Soticlestat
CDKL5 Deficiency Disease
TakedaSmall moleculePhase 2Dormant
CCC
54/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 39/ 100
- Competitive Position
- 95/ 100
Competitive context
1 Active assets in the CDKL5 Deficiency Disease cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Ganaxolone Marinus Pharmaceuticals | Phase 3 | B |
Benzeneethanamine, N-ethyl-?-methyl-4-(trifluoromethyl)-, hydrochloride, (±)- Zogenix, Inc. | Phase 3 | B |
Same molecule, other indications
Soticlestat is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →